Abraham Ceesay sold $2.0M of RAPP
Chief Executive Officer at Rapport Therapeutics, Inc.. 76,420 shares at an average of $26.32, traded Sep 17, 2025, filed Sep 19, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.0M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-209062, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2025 | SOpen-market sale Common Stock10b5-1 | -39,435 | $26.30 | $1.0M | 586,812 | Sep 19, 2025 |
| Sep 17, 2025 | SOpen-market sale Common Stock10b5-1 | -1,400 | $26.87 | $38k | 585,412 | Sep 19, 2025 |
| Sep 17, 2025 | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -34,885 | $26.30 | $918k | 46,844 | Sep 19, 2025 |
| Sep 17, 2025 | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -700 | $27.04 | $19k | 46,144 | Sep 19, 2025 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 22Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $282k 10,000 shares | -6% | |
| 17Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $303k 10,115 shares | -3% | |
| 27Weak | RAPPsell Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $58k 2,014 shares | -1% | |
| 1Weak | Rapport Therapeutics, Inc. | David Bredt Chief Scientific Officer | $247k 8,500 shares | -2% | |
| 27Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $320k 10,916 shares | -2% | |
| 27Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $285k 10,916 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.